SURMOUNT-3

SURMOUNT-3 asks a question patients ask constantly: if lifestyle change is already working, does adding a drug still help? The design answers it directly. Everyone first completed a 12-week intensive lifestyle intervention, and only those who had already lost at least 5% of their body weight went on to randomization. The people who entered the trial proper were, by definition, lifestyle responders.

579 of them were randomized to tirzepatide at the maximum tolerated dose (10 or 15 mg weekly) or to placebo for 72 more weeks, with the lifestyle program continuing throughout. Wadden and colleagues published it in Nature Medicine in 2023.

Measured from randomization — that is, on top of the loss they had already banked — the tirzepatide group lost a further 18.4%, while the placebo group regained 2.5%. The gap is 20.8 percentage points. Put another way, 87.5% of the tirzepatide group achieved at least 5% additional weight reduction versus 16.5% on placebo, even though both groups stayed in the behavioral program.

That placebo result is the part worth sitting with. These were people who had just proven they could lose weight through diet and activity, doing the same program, with clinical support — and on average they drifted back up. It is the same physiology STEP 4 demonstrated from the other direction. The common confusion is framing medication as what you try after lifestyle fails; SURMOUNT-3 tested it in people for whom lifestyle had succeeded, and it still added a great deal.

Worth asking your clinician: whether your plan requires a documented lifestyle attempt before it will approve a drug, how to keep the behavioral work going once medication starts doing some of the appetite work, and what protein and resistance-training targets to hold to. Our SURMOUNT-3 deep dive, intensive behavioral therapy entry, and protein calculator cover the practical side.